Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536145 · ClinicalTrials.gov registry record · Phase 1
CP-751,871 Treatment For Patients With Multiple Myeloma
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01536145 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 47 participants.
The verdict
NCT01536145, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Interventions
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-12 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536145
The ClinicalTrials.gov registry entry for NCT01536145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-751,871 is the first listed.
NCT01536145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01536145 about?
NCT01536145 is a clinical study titled "CP-751,871 Treatment For Patients With Multiple Myeloma". This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
What is the current status of trial NCT01536145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2003-12. Estimated completion is 2008-06.
What interventions are being tested in trial NCT01536145?
The interventions under investigation include: CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT01536145?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.